Single nucleotide polymorphisms (SNPs) have been associated with prostate cancer (PCa) risk and tumor aggressiveness in retrospective studies. To assess the value of genotyping in a clinical setting, we evaluated the correlation between three genotypes (rs1447295 and rs6983267[8q24] and rs4054823[17p12]) and prostatic biopsy outcome prospectively in a French population of Caucasian men. Five hundred ninety-eight patients with prostatic-specific antigen (PSA) >4 ng/mL or abnormal digital rectal examination (DRE) participated in this prospective, multicenter study. Age, familial history of PCa, body mass index (BMI), data of DRE, International Prostate Symptom Score (I-PSS) score, PSA value and prostatic volume were collected prospectively before prostatic biopsy. Correlation between genotypes and biopsy outcome (positive or negative) and Gleason score (≤6 or >6) were studied by univariate and multivariable analysis. rs1447295 and rs6983267 risk variants were found to be associated with the presence of PCa in univariate analysis. rs6983267 genotype remained significantly linked to a positive biopsy (odds ratio [OR] = 1.66, 95% confidence interval [CI]: 1.06-2.59, P = 0.026) in multivariable analysis, but rs1447295 genotype did not (OR = 1.47, 95% CI: 0.89-2.43, P = 0.13). When biopsy outcome was stratified according to Gleason score, risk variants of rs1447295 were associated with aggressive disease (Gleason score ≥7) in univariate and multivariable analysis (OR = 2.05 95% CI: 1.10-3.79, P = 0.023). rs6983267 GG genotype was not related to aggressiveness. The results did not reach significance concerning rs4054823 for any analysis. This inaugural prospective evaluation thus confirmed potential usefulness of genotyping PCa assessment. Ongoing clinical evaluation of larger panels of SNPs will detail the actual impact of genetic markers on clinical practice.
This is a preview of subscription content, log in to check access.
This study was funded by a national public grant for clinical research (PHRC 2008).
Jemal A, Siegel R, Xu J, Ward E. (2010) Cancer statistics, 2010. CA Cancer J. Clin. 60:277–300.CrossRefGoogle Scholar
Marberger M, et al. (2008) New treatments for localized prostate cancer. Urology. 72:S36–43.CrossRefGoogle Scholar
Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. (2008) An updated catalog of prostate cancer predictive tools. Cancer. 113:3075–99.CrossRefGoogle Scholar
Nogueira L, Corradi R, Eastham JA. (2010) Other biomarkers for detecting prostate cancer. BJU Int. 105:166–9.CrossRefGoogle Scholar
Lughezzani G, et al. (2010) Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur. Urol. 58:687–700.CrossRefGoogle Scholar
Gudmundsson J, et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39:631–7.CrossRefGoogle Scholar
Yeager M, et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39:645–9.CrossRefGoogle Scholar
Pal P, et al. (2009) Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry. Prostate. 69:1548–56.CrossRefGoogle Scholar
Suuriniemi M, et al. (2007) Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol. Biomarkers Prev. 16:809–14.CrossRefGoogle Scholar
Wang L, et al. (2007) Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res. 67:2944–50.CrossRefGoogle Scholar
Cussenot O, et al. (2008) Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin. Cancer Res. 14:5635–9.CrossRefGoogle Scholar
Hamano T, et al. (2010) Association of SNP rs1447295 and microsatellite marker DG8S737 with familial prostate cancer and high grade disease. J. Urol. 184:738–42.CrossRefGoogle Scholar
Wiklund FE, et al. (2009) Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol. Biomarkers Prev. 18:1659–62.CrossRefGoogle Scholar
Penney KL, et al. (2009) Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin. Cancer Res. 15:3223–30.CrossRefGoogle Scholar
Salinas CA, et al. (2009) Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate. 69:363–72.CrossRefGoogle Scholar
Cheng I, et al. (2010) Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol. Biomarkers Prev. 19:2124–32.CrossRefGoogle Scholar
Xu J, et al. (2010) Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 107:2136–40.CrossRefGoogle Scholar
Nam RK, et al. (2009) Utility of incorporating genetic variants for the early detection of prostate cancer. Clin. Cancer Res. 15:1787–93.CrossRefGoogle Scholar
Amundadottir LT, et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38:652–8.CrossRefGoogle Scholar
Fitzgerald LM, et al. (2009) Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin. Cancer Res. 15:3231–7.CrossRefGoogle Scholar
Zheng SL, et al. (2008) Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358:910–9.CrossRefGoogle Scholar